Heme oxygenase-1 induction may explain the antioxidant profile of aspirin

Biochemical and Biophysical Research Communications

Volumn 308, Issue 4, 2003, Pages 956-960

  Grosser, Nina ^a   Abate, Aida ^a,b   Oberle, Stefanie ^a   Vreman, Hendrik J ^b   Dennery, Phyllis A ^b   Becker, Jan C ^c   Pohle, Thorsten ^c   Seidman, Daniel S ^d   Schröder, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antioxidant; Aspirin; Bilirubin; Carbon monoxide; Cell injury; Cytoprotection; Endothelial cells; Gene expression; Heme oxygenase; Nitric oxide

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; BILIRUBIN; CARBON MONOXIDE; HEME OXYGENASE 1; HYDROGEN PEROXIDE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANTIOXIDANT ACTIVITY; ARTICLE; CATALYSIS; CELL CULTURE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TOXICITY; UMBILICAL VEIN;

EID: 0041659120     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01504-3     Document Type: Article

References (38)

1. Fuster V., Dyken M.L., Vokonas P.S., Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group, Circulation. 87:1993;659-675.
2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients, BMJ 324 (2002) 71-86.
3. Samuelsson B., Granstrom E., Green K., Hamberg M., Hammarstrom S. Prostaglandins. Annu. Rev. Biochem. 44:1975;669-695.
4. Reilly I.A., FitzGerald G.A. Aspirin in cardiovascular disease. Drugs. 35:1988;154-176.
5. Aruoma O.I., Halliwell B. The iron-binding and hydroxyl radical scavenging action of anti-inflammatory drugs. Xenobiotica. 18:1988;459-470.
6. Woollard A.C., Wolff S.P., Bascal Z.A. Antioxidant characteristics of some potential anticataract agents. Studies of aspirin, paracetamol, and bendazac provide support for an oxidative component of cataract. Free Radic. Biol. Med. 9:1990;299-305.
7. Podhaisky H.P., Abate A., Polte T., Oberle S., Schröder H. Aspirin protects endothelial cells from oxidative stress - possible synergism with vitamin E. FEBS Lett. 417:1997;349-351.
8. Steer K.A., Wallace T.M., Bolton C.H., Hartog M. Aspirin protects low density lipoprotein from oxidative modification. Heart. 77:1997;333-337.
9. Wu R., Lamontagne D., de Champlain J. Antioxidative properties of acetylsalicylic acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 105:2002;387-392.
10. Yang L., Quan S., Abraham N.G. Retrovirus-mediated HO gene transfer into endothelial cells protects against oxidant-induced injury. Am. J. Physiol. 277:1999;L127-L133.
11. Suttner D.M., Sridhar K., Lee C.S., Tomura T., Hansen T.N., Dennery P.A. Protective effects of transient HO-1 overexpression on susceptibility to oxygen toxicity in lung cells. Am. J. Physiol. 276:1999;L443-L451.
12. Platt J.L., Nath K.A. Heme oxygenase: protective gene or Trojan horse. Nat. Med. 4:1998;1364-1365.
13. Maines M.D. The heme oxygenase system: a regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37:1997;517-554.
14. Stocker R., Yamamoto Y., McDonagh A.F., Glazer A.N., Ames B.N. Bilirubin is an antioxidant of possible physiological importance. Science. 235:1987;1043-1046.
15. Coceani F. Carbon monoxide in vasoregulation: the promise and the challenge. Circ. Res. 86:2000;1184-1186.
16. Yee E.L., Pitt B.R., Billiar T.R., Kim Y.M. Effect of nitric oxide on heme metabolism in pulmonary artery endothelial cells. Am. J. Physiol. 271:1996;L512-L518.
17. Polte T., Abate A., Dennery P.A., Schröder H. Heme oxygenase-1 is a cGMP-inducible endothelial protein and mediates the cytoprotective action of nitric oxide. Arterioscler. Thromb. Vasc. Biol. 20:2000;1209-1215.
18. Oberle S., Polte T., Abate A., Podhaisky H.P., Schröder H. Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ. Res. 82:1998;1016-1020.
19. Immenschuh S., Ramadori G. Gene regulation of heme oxygenase-1 as a therapeutic target. Biochem. Pharmacol. 60:2000;1121-1128.
20. Suda K., Rothen-Rutishauser B., Gunthert M., Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In Vitro Cell Dev. Biol. Anim. 37:2001;505-514.
21. Oberle S., Schröder H. Ferritin may mediate SIN-1-induced protection against oxidative stress. Nitric Oxide. 1:1997;308-314.
22. Polte T., Oberle S., Schröder H. Nitric oxide protects endothelial cells from tumor necrosis factor- alpha-mediated cytotoxicity: possible involvement of cyclic GMP. FEBS Lett. 409:1997;46-48.
23. Flick D.A., Gifford G.E. Comparison of in vitro cell cytotoxic assays for tumor necrosis factor. J. Immunol. Methods. 68:1984;167-175.
24. Motterlini R., Foresti R., Intaglietta M., Winslow R.M. NO-mediated activation of heme oxygenase: endogenous cytoprotection against oxidative stress to endothelium. Am. J. Physiol. 270:1996;H107-H114.
25. Vreman H.J., Stevenson D.K. Heme oxygenase activity as measured by carbon monoxide production. Anal. Biochem. 168:1988;31-38.
26. Appleton S.D., Chretien M.L., McLaughlin B.E., Vreman H.J., Stevenson D.K., Brien J.F., Nakatsu K., Maurice D.H., Marks G.S. Selective inhibition of heme oxygenase, without inhibition of nitric oxide synthase or soluble guanylyl cyclase, by metalloporphyrins at low concentrations. Drug Metab. Dispos. 27:1999;1214-1219.
27. Monobe H., Yamanari H., Nakamura K., Ohe T. Effects of low-dose aspirin on endothelial function in hypertensive patients. Clin. Cardiol. 24:2001;705-709.
28. Ranke C., Hecker H., Creutzig A., Alexander K. Dose-dependent effect of aspirin on carotid atherosclerosis. Circulation. 87:1993;1873-1879.
29. Kodama M., Yamasaki Y., Sakamoto K., Yoshioka R., Matsuhisa M., Kajimoto Y., Kosugi K., Ueda N., Hori M. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb. Res. 97:2000;239-245.
30. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., Pratico D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 106:2002;1282-1287.
31. Husain S., Andrews N.P., Mulcahy D., Panza J.A., Quyyumi A.A. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation. 97:1998;716-720.
32. Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. Trends Pharmacol. Sci. 10:1989;453-458.
33. Clarke R.J., Mayo G., Price P., FitzGerald G.A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med. 325:1991;1137-1141.
34. Yachie A., Niida Y., Wada T., Igarashi N., Kaneda H., Toma T., Ohta K., Kasahara Y., Koizumi S. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. J. Clin. Invest. 103:1999;129-135.
35. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin. Chem. 46:2000;1723-1727.
36. Hopkins P.N., Wu L.L., Hunt S.C., James B.C., Vincent G.M., Williams R.R. Higher serum bilirubin is associated with decreased risk for early familial coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 16:1996;250-255.
37. Otterbein L.E., Bach F.H., Alam J., Soares M., Tao Lu H., Wysk M., Davis R.J., Flavell R.A., Choi A.M. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nat. Med. 6:2000;422-428.
38. N. Grosser, H. Schröder, Aspirin protects endothelial cells from oxidant damage via the nitric oxide-cGMP pathway, Arterioscler. Thromb. Vasc. Biol. (2003) [Epub ahead of print].